Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 14 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical StudyRecruitingNCT06538896Phase 2
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung CancerRecruitingNCT06538012Phase 1/2
• AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06537011Phase 2
• VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSRecruitingNCT06536959Phase 2
• Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLCRecruitingNCT06536868Phase 2
• Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsRecruitingNCT06535607Phase 2
• CD8 PET Imaging in Metastatic Solid TumoursRecruitingNCT06534190Phase 2
• TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast CancerRecruitingNCT06532812Phase 1/2
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal CancerRecruitingNCT06532799Phase 1/2
• Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLCRecruitingNCT06532591Phase 2
• Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial CarcinomaRecruitingNCT06532539Phase 2
• Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine DifferentiationNot yet recruitingNCT06531291Phase 2
• A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06530914Phase 2
• Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract CarcinomaNot yet recruitingNCT06530823Phase 2
• A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)RecruitingNCT06530251Phase 1/2
• A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast CancerNot yet recruitingNCT06530082Phase 1
• Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer PatientsRecruitingNCT06529718Phase 2
• Tislelizumab in People With Colorectal CancerRecruitingNCT06529523Phase 2
• Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung AdenocarcinomaRecruitingNCT06528847Phase 2
• Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced LeiomyosarcomaRecruitingNCT06528769Phase 2
• Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerNot yet recruitingNCT06528483Phase 2
• Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B CirrhosisRecruitingNCT06526104Phase 2
• Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound HistotripsyRecruitingNCT06524570Phase 1
• A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingNCT06524544Phase 3
• Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination TherapyNot yet recruitingNCT06523049Phase 2
• A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer PatientsRecruitingNCT06522828Phase 2
• Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal CancerRecruitingNCT06521866Phase 2
• Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal CancerRecruitingNCT06520683Phase 3
• Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal MetastasisRecruitingNCT06519591Phase 2
• PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver MetastasesRecruitingNCT06519266Phase 3
• Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With MedulloblastomaRecruitingNCT06514898Phase 1
• A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With AdebrelimabNot yet recruitingNCT06513221Phase 2
• Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular CarcinomaNot yet recruitingNCT06512467Phase 2
• A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung CancerRecruitingNCT06512207Not applicable
• Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCCRecruitingNCT06510660Phase 2
• A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian CancerNot yet recruitingNCT06509971Phase 2
• Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaRecruitingNCT06508463Phase 1
• Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCCNot yet recruitingNCT06508229Phase 2
• A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast CancerRecruitingNCT06508216Phase 1/2
• A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)RecruitingNCT06506292Phase 2
• A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder CancerRecruitingNCT06503614Phase 2
• First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial CancerRecruitingNCT06502743Phase 2
• [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast CancerRecruitingNCT06502691Phase 1/2
• Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialRecruitingNCT06498635Phase 3
• Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With EnvafolimabRecruitingNCT06498622Phase 2
• A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer PatientsRecruitingNCT06497985Phase 3
• Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCRecruitingNCT06497530Phase 2
• Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic CancerRecruitingNCT06496373Early Phase 1
• Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerRecruitingNCT06495125Phase 2
• Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCCRecruitingNCT06494943Phase 1/2
• A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer PatientsRecruitingNCT06493760Phase 2
• Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal CancerRecruitingNCT06493019Phase 2
• Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaRecruitingNCT06492954Phase 1
• High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast CancerRecruitingNCT06492759Phase 2
• Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.RecruitingNCT06492421Phase 2
• Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Phase 2
• RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric CancerNot yet recruitingNCT06492317Phase 2
• Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic CancerRecruitingNCT06491472Phase 2
• The Sagittarius TrialRecruitingNCT06490536Phase 3
• Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to ImmunotherapyRecruitingNCT06490068Phase 2
• A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLCNot yet recruitingNCT06485557Phase 3
• A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHLRecruitingNCT06484920Phase 2
• A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung CancerRecruitingNCT06483282Phase 2
• Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility StudyRecruitingNCT06482788Phase 2
• Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung CancerRecruitingNCT06480864Not applicable
• An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06480552Phase 1
• SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line TreatmentNot yet recruitingNCT06480136Phase 2
• A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell CarcinomaNot yet recruitingNCT06478264Phase 2
• Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLCNot yet recruitingNCT06475755Phase 2
• Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial CancerNot yet recruitingNCT06475599Phase 3
• Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic CancerRecruitingNCT06475326Phase 2
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT06475300Phase 2
• Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLRecruitingNCT06475235Phase 1
• A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell CarcinomaNot yet recruitingNCT06472895Phase 1/2
• Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPCRecruitingNCT06472713Phase 2
• Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast CancerRecruitingNCT06472583Phase 2
• AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDACRecruitingNCT06472037Phase 2
• A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast CancerRecruitingNCT06471673Phase 1/2
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast CancerRecruitingNCT06471205Phase 2
• Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast CancerNot yet recruitingNCT06470672Phase 2
• To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast CancerNot yet recruitingNCT06470633Phase 2
• Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder CancerRecruitingNCT06470282Phase 1/2
• Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingNCT06470256Phase 1
• A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsNot yet recruitingNCT06469879Phase 3
• A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRecruitingNCT06469281Phase 1
• A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT06468358Phase 1/2
• Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLCRecruitingNCT06467617Phase 2
• A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed ImmunotherapyRecruitingNCT06467500Phase 2
• Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingNCT06467357Phase 3
• Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.Not yet recruitingNCT06464614Phase 2
• AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMARecruitingNCT06464068Phase 2
• A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaRecruitingNCT06463834Phase 2
• Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal CancerRecruitingNCT06462053Phase 2
• Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical CancerRecruitingNCT06459687Phase 3
• A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal CancerRecruitingNCT06457503Phase 4
• Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB PatientsRecruitingNCT06457477Not applicable
• Effectiveness of Pucotenlimab Combined With Standard Chemotherapy RegimenRecruitingNCT06456892Phase 1/2
• Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLCNot yet recruitingNCT06456138Phase 1/2
• GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06455410Phase 2
• Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLMRecruitingNCT06455254Phase 2

← Immune Checkpoint Inhibitors overview